HR Execs on the Move

Third Wave Technologies

www.twt.com

 
Third Wave Technologies, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.twt.com
  • 502 S Rosa Rd
    Madison, WI USA 53719
  • Phone: 608.273.8933

Executives

Name Title Contact Details
Judy Busby
Exec Director of Operations, Human Resources, and Customer Service Profile

Similar Companies

Merck Life Science

Created by the 1975 merger of Sigma Chemical Company and Aldrich Chemical Company, Sigma-Aldrich since grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000 at the time of its acquisition by Merck.

Ziemer USA INC

Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunocore

Immunocore is a privately owned British clinical-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs to treat cancer, infectious diseases and autoimmune diseases using soluble T-cell receptor technology.

Altimmune

Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of infectious disease.

Inflammatix

Inflammatix, Inc. is a venture-backed startup located in the San Francisco Bay Area that is building novel diagnostics for acute infections and sepsis based on our unique immune biomarkers. Approximately $10 billion / year is spent trying to diagnose acute infections, but current technologies that focus on `finding the bug` are (1) slow and (2) effective in fewer than 30% of cases. Inflammatix has developed a statistically rigorous, extensively validated diagnostic method that `reads` the immune system. Our HostDx™ tests report clinically actionable information on the presence, type (bacterial or viral), and severity of infection in all patients. They have been extensively validated and published in top-tier medical journals. After this initial product, Inflammatix plans to develop and commercialize additional novel diagnostic tests to address significant unmet clinical needs.